Guidelines International Network (GIN)
Powered by EBSCO

Guidelines International Network

3111 - 3120 of 3501 results found

Systemic Therapy for Metastatic Urothelial Cancer: An Endorsement of a Portion of the European Association of Urology Guideline on Muscle-Invasive and Metastatic Bladder Cancer

Guideline Contact
Judy Brown; pebconc@mcmaster.ca
Date for Review
In Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario), we have an annual review process for each guideline after it is completed. Guidelines are reviewed every fall after they are older than 1 year.
Publication Date
09/08/2022
Publication Scope
Guidelines
treatment
Countries of Application
Canada
Guideline Publication Status
Published
Languages
English
Publication Year
2022

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Clinical Practice Guideline Update

MeSH Terms
Neoplasms (C04); Breast Neoplasms (C04.588.180); Pharmacologic Actions (D27.505)
Guideline Contact
guidelines@asco.org
Publication Date
25-Jun-18
Publication Scope
prognosis
treatment
Countries of Application
United States
Guideline Publication Status
Under Review
Languages
English
Authors
ASCO (US)
Publication Year
2018

Systemic Therapy for Recurrent Epithelial Ovarian Cancer

MeSH Terms

Ovarian Neoplasms (C04.588.322.455); Neoplasm Recurrence; Local (C04.697.655); Neoplasm Metastasis (C04.697.650)

Guideline Contact
Cindy Walker-Dilks (pebconc@mcmaster.ca)
Publication Scope
treatment
Countries of Application
Canada
Guideline Publication Status
Published
Languages
English
Authors
McMaster University (CA)
Publication Year
2017

Systemic therapy for unresectable advanced or metastatic pancreatic and midgut neuroendocrine tumours: Version 2

MeSH Terms

Neuroendocrine Carcinoma, Gastroenteropancreatic neuroendocrine tumor, Phase 3 Clinical Trial, Phase 4 Clinical Trial, Randomized Controlled Trial, Guideline, Systematic Review, Quality Assessment, Adult, Octreotide, 177Lu-Dotatate, 90y-Dotatate

Guideline Contact
Roxanne Cosby; cosbyr@mcmaster.ca
Keywords
Guideline, Midgut Neuroendocrine Tumours, Pancreatic Neuroendocrine Tumours, Systemic Therapy, Systematic Review
Date for Review
The Program in Evidence-based Care (PEBC), Ontario Health (CCO) has an annual review process for each guideline. Guidelines are reviewed every fall, one year after they are completed
Publication Date
March 2024
Date of Last Evidence Search
October 30, 2023
Methods Applied
Evidence-based; Systematic review-based; External review; Evidence quality assessment; Patient/survivor/caregiver participation
Publication Scope
treatment
Countries of Application
Canada
Guideline Publication Status
Published
Languages
English
Authors
PEBC (Program in evidenced-based care)
Publication Year
2024

Systemic therapy in men with metastatic castration-resistant prostate cancer

MeSH Terms

Drug Therapy (E02.319); Antineoplastic Agents (D27.505.954.248); Drug Therapy; Combination (E02.319.310); Prostatic Neoplasms (C04.588.945.440.770)

Guideline Contact
Cindy Walker-Dilks (pebconc@mcmaster.ca)
Publication Scope
treatment
Countries of Application
Canada
Guideline Publication Status
Published
Languages
English
Authors
McMaster University (CA)
Publication Year
2005

Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline

MeSH Terms
Prostatic Neoplasms; Castration-Resistant (C04.588.945.440.770.500)
Guideline Contact
guidelines@asco.org
Publication Date
08-Sep-14
Publication Scope
management
Countries of Application
United States
Guideline Publication Status
Published
Languages
English
Authors
ASCO (US)
Publication Year
2014